Specify a stock or a cryptocurrency in the search bar to get a summary
Ascendis Pharma AS
ASNDAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/" for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Address: Tuborg Boulevard 12, Hellerup, Denmark, 2900
Analytics
WallStreet Target Price
0.34 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ASND
Dividend Analytics ASND
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ASND
Stock Valuation ASND
Financials ASND
Results | 2019 | Dynamics |